EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial

Magdalena K Scheck, Thorsten O Goetze, Thomas J Ettrich, Harald Schmalenberg, Michael Clemens, Rolf Mahlberg, Steffen Heeg, Stephan Kanzler, Gunnar Hapke, Peter Thuss-Patience, Angelika Kestler, Anne Treschl und 7 weitere

Oncology Research and Treatment · 2024

DOI: 10.1159/000541174 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Magdalena K Scheck und 18 weiteren Autor:innen. Beteiligte Einrichtung: Klinikum rechts der Isar, TU München, Klinik für Innere Medizin III, Munich, Germany, magdalena.scheck@web.de. Hauptthemen laut MEDLINE: Paclitaxel, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Ramucirumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In squamous cell carcinoma of the esophagus (ESCC), therapeutical options in 2nd-line treatment are scarce with immune checkpoint inhibition being the only approved one. Ramucirumab/paclitaxel is an approved 2nd-line treatment in metastatic esophagogastric adenocarcinoma. We assessed safety and efficacy of ramucirumab/paclitaxel for ESCC.

Methods

This prospective, randomized, open-label, multicenter, phase II trial evaluated paclitaxel (80 mg/m2 days 1, 8, 15) plus ramucirumab (8 mg/kg days 1, 15) (investigational arm A) versus paclitaxel alone (80 mg/m2 days 1, 8, 15) (standard arm B), both q4w, in advanced/metastatic ESCC refractory or intolerant to fluoropyrimidine and platinum-based drugs. Primary endpoint was overall survival (OS) rate at 6 months.

Results

From 3/2019 to 4/2021, 21/186 planned patients were included (arm A 11 patients; arm B 10 patients) in 9 German centers. Due to slow accrual, the study was terminated prematurely. OS at 6 months was 72.7% for ramucirumab/paclitaxel and 50.0% for paclitaxel. The study design did not allow statistical comparison of the arms. PFS (3.8 vs. 3.5 months), OS (12.1 vs. 9.2 months), ORR (18.2% vs. 20.0%) and DCR (54.5% vs. 60.0%) were comparable in both arms. Most common treatment-related adverse events (TRAEs) in arm A were leucopenia (54.5%), fatigue (27.3%), and peripheral sensory neuropathy (18.2%). 27.3% in arm A and 50.0% in arm B had TRAEs ≥ grade 3.

Conclusion

Ramucirumab/paclitaxel shows an acceptable tolerability and numerically improved OS at 6 months. Due to the small number of patients, the current trial must be considered exploratory and more data are needed in this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsRamucirumabAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAgedProspective StudiesAdultSurvival Rate

Stichwörter der Autor:innen

Advanced esophagus squamous cancerAntiangiogenicPaclitaxelRamucirumabSecond-line

Substanzen

PaclitaxelRamucirumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Klinikum rechts der Isar, TU München, Klinik für Innere Medizin III, Munich, Germany, magdalena.scheck@web.de.
  • Krankenhaus Nordwest, University Cancer Center Frankfurt, Germany and Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Frankfurt, Germany.
  • Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany.
  • Städtisches Klinikum Dresden, Medizinische Klinik IV, Dresden, Germany.
  • CaritasKlinikum Saarbrücken, Klinik für Hämatologie und Onkologie, Saarbrücken, Germany.
  • Klinikum Mutterhaus Trier, Innere Medizin I, Trier, Germany.

Zitieren

APA

Scheck, M. K., Goetze, T. O., Ettrich, T. J., Schmalenberg, H., Clemens, M., Mahlberg, R., Heeg, S., Kanzler, S., Hapke, G., Thuss-Patience, P., Kestler, A., Treschl, A., Heidel, S., Schiemer, M., Sookthai, D., Junge, S., Pauligk, C., Al-Batran, S. E., & Lorenzen, S. (2024). Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial. Oncology Research and Treatment. https://doi.org/10.1159/000541174

Vancouver

Scheck MK, Goetze TO, Ettrich TJ, Schmalenberg H, Clemens M, Mahlberg R, et al. Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial. Oncology Research and Treatment. 2024. doi:10.1159/000541174

BibTeX
@article{Scheck2024,
  author = {Scheck, Magdalena K and Goetze, Thorsten O and Ettrich, Thomas J and Schmalenberg, Harald and Clemens, Michael and Mahlberg, Rolf and Heeg, Steffen and Kanzler, Stephan and Hapke, Gunnar and Thuss-Patience, Peter and Kestler, Angelika and Treschl, Anne and Heidel, Stefan and Schiemer, Moritz and Sookthai, Disorn and Junge, Sabine and Pauligk, Claudia and Al-Batran, Salah-Eddin and Lorenzen, Sylvie},
  title = {Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial},
  journal = {Oncology Research and Treatment},
  year = {2024},
  doi = {10.1159/000541174}
}
Kostenlos starten →